Graft-versus-host disease: Difference between revisions
Shyam Patel (talk | contribs) No edit summary |
Shyam Patel (talk | contribs) |
||
| Line 40: | Line 40: | ||
[[Graft-versus-host disease medical therapy|Medical Therapy]] | [[Graft-versus-host disease medical therapy|Medical Therapy]] | ||
Ruxolitinib has been used for GvHD that is refractory to steroids.<ref name="pmid28444730">{{cite journal| author=Assouan D, Lebon D, Charbonnier A, Royer B, Marolleau JP, Gruson B| title=Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease. | journal=Br J Haematol | year= 2017 | volume= | issue= | pages= | pmid=28444730 | doi=10.1111/bjh.14679 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28444730 }} </ref> | The treatment of GvHD focuses on immunosuppression. Immunosuppression is usually achieved by administering steroids, auch as prednisone or methylprednisolone.<ref name="pmid17784964">{{cite journal| author=Jacobsohn DA, Vogelsang GB| title=Acute graft versus host disease. | journal=Orphanet J Rare Dis | year= 2007 | volume= 2 | issue= | pages= 35 | pmid=17784964 | doi=10.1186/1750-1172-2-35 | pmc=2018687 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17784964 }} </ref> Alternative agents include immunophilins like cyclosporine or tacrolimus.<ref name="pmid17784964">{{cite journal| author=Jacobsohn DA, Vogelsang GB| title=Acute graft versus host disease. | journal=Orphanet J Rare Dis | year= 2007 | volume= 2 | issue= | pages= 35 | pmid=17784964 | doi=10.1186/1750-1172-2-35 | pmc=2018687 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17784964 }} </ref> Ruxolitinib has been used for GvHD that is refractory to steroids.<ref name="pmid28444730">{{cite journal| author=Assouan D, Lebon D, Charbonnier A, Royer B, Marolleau JP, Gruson B| title=Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease. | journal=Br J Haematol | year= 2017 | volume= | issue= | pages= | pmid=28444730 | doi=10.1111/bjh.14679 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28444730 }} </ref> | ||
| [[Graft-versus-host disease primary prevention|Primary Prevention]] | | [[Graft-versus-host disease primary prevention|Primary Prevention]] | ||
Revision as of 06:37, 11 June 2017
|
Graft-versus-host disease |
|
Differentiating Graft-versus-host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Graft-versus-host disease On the Web |
|
American Roentgen Ray Society Images of Graft-versus-host disease |
|
Risk calculators and risk factors for Graft-versus-host disease |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: GVHD
Overview
Graft-versus-host disease (GvHD) is a condition characterized by recipient tissue damage that arise from immunological activation of donor T lymphocytes. It typically occurs in the setting of bone marrow transplantation. Donor T cells mount a response against foreign host cells in the gastrointestinal system, liver, and skin.
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Graft-versus-host disease from Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | CT | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy The treatment of GvHD focuses on immunosuppression. Immunosuppression is usually achieved by administering steroids, auch as prednisone or methylprednisolone.[1] Alternative agents include immunophilins like cyclosporine or tacrolimus.[1] Ruxolitinib has been used for GvHD that is refractory to steroids.[2]
| Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies
Related Chapters
- ↑ 1.0 1.1 Jacobsohn DA, Vogelsang GB (2007). "Acute graft versus host disease". Orphanet J Rare Dis. 2: 35. doi:10.1186/1750-1172-2-35. PMC 2018687. PMID 17784964.
- ↑ Assouan D, Lebon D, Charbonnier A, Royer B, Marolleau JP, Gruson B (2017). "Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease". Br J Haematol. doi:10.1111/bjh.14679. PMID 28444730.